🟢 Summit Therapeutics is trading 4.03% up today after AstraZeneca completed its $2 billion equity investment

Summit Therapeutics is trading 4.03% up at $17.43 on October 5, 2026, after announcing AstraZeneca completed its $2 billion equity investment; the announcement does not explicitly attribute the intraday share move to the investment.

• Proceeds are intended to accelerate development of ivonescimab across multiple solid-tumor settings.
• The investment implies a common-stock price of $18.36.